An Open Label, Phase I Study of Copanlisib to Evaluate the Pharmacokinetics, Safety and Tolerability in Chinese Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2018
At a glance
- Drugs Copanlisib (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Bayer
- 17 Dec 2018 Planned End Date changed from 3 Sep 2019 to 3 Apr 2020.
- 17 Dec 2018 Planned primary completion date changed from 11 Jun 2019 to 4 Oct 2019.
- 25 May 2018 Status changed from not yet recruiting to recruiting.